

SERENA MARCHI

Curriculum Vitae

Department of Molecular and Developmental Medicine, University of Siena
Polo di San Miniato, via Aldo Moro 2, 53100 Siena, Italy
serena.marchi2@unisi.it | +39 338 2954582
ORCID 0000-0002-6817-2461 | Scopus Author ID 57193380868

CURRENT POSITION

Dates: 1 June 2024 – 31 May 2030

Institution: University of Siena, Department of Molecular and Developmental Medicine, Polo di San Miniato, via Aldo Moro 2, 53100 Siena, Italy

Academic sector: Hygiene and Public Health

Position: Tenure-track Researcher (Ricercatrice a tempo determinato, L. 79/2022)

PREVIOUS ACADEMIC EXPERIENCE

16 April 2024 – 31 May 2024 · Research fellowship

Institution: University of Siena, Department of Molecular and Developmental Medicine

Project: Epidemiology of vaccine-preventable and non-vaccine-preventable infectious diseases

16 March 2021 – 15 March 2024 · Postdoctoral research fellowship

Institution: University of Siena, Department of Biotechnology, Chemistry and Pharmacy

Project: Validation and application of analytical processes for the assessment of in vitro cytotoxicity and antiviral activity of candidate compounds (TUSCAVIR.NET – Tuscany Antiviral Research Network, Regione Toscana, Bando Salute 2018)

16 March 2020 – 15 March 2021 · Postdoctoral research fellowship

Institution: University of Siena, Department of Molecular and Developmental Medicine

Project: Standardisation and development of assays for the assessment of influenza vaccine correlates of protection (FLUCOP, IMI Joint Undertaking, funded by the EU Seventh Framework Programme)

15 March 2018 – 14 March 2020 · Postdoctoral research fellowship

Institution: University of Siena, Department of Molecular and Developmental Medicine

Project: Development of serological assays for the quantification of anti-neuraminidase antibodies (ABNEURA, Regione Toscana, POR FSE 2014–2020)

OTHER PROFESSIONAL EXPERIENCE

14 October 2024 – 13 October 2025 · VisMederi srl, Siena

Collaboration contract for serological analysis of emerging pathogens and project management on European life-science projects.

1 August 2022 – 31 January 2023 · VisMederi srl, Siena

Collaboration contract for consultancy and standardisation of serological assays for the assessment of immunity to flaviviruses.

March 2011 – October 2012 · Regional Reference Centre for Microbiological Emergencies (C.R.R.E.M.), Sant'Orsola-Malpighi University Hospital, Bologna

Collaboration contract for the development of a monitoring and surveillance system for the safety of blood and organ donation with respect to emerging infections, in particular vector-borne diseases.

EDUCATION AND TRAINING

Specialisation in Microbiology and Virology

Institution: University of Siena, Department of Medical Biotechnologies

Dates: 1 November 2020 – 31 October 2024; awarded 21 November 2024

Final mark: 70/70 cum laude

Thesis: Epidemiology of severe acute respiratory infections at Santa Maria alle Scotte University Hospital, Siena, in the 2023/2024 season: virological and phylogenetic analysis of influenza and SARS-CoV-2

PhD in Biochemistry and Molecular Biology

Institution: University of Siena, Department of Biotechnology, Chemistry and Pharmacy

Dates: 1 November 2015 – 31 October 2018; awarded 28 February 2019

Thesis: Seroepidemiological study of Zika virus in selected West African countries between 2007 and 2012

MSc in Health Biology

Institution: University of Siena, Department of Molecular and Developmental Medicine

Dates: November 2012 – April 2015; awarded 21 April 2015

Final mark: 110/110 cum laude

Thesis: Seroprevalence of Toscana virus infection in Italy

BSc in Biomedical Laboratory Techniques

Institution: Alma Mater Studiorum – University of Bologna, Faculty of Medicine and Surgery

Dates: October 2007 – October 2010; awarded 26 October 2010

Final mark: 110/110 cum laude

Thesis: Chikungunya virus and Dengue fever: a seroprevalence study in the Republic of Benin

PROFESSIONAL QUALIFICATIONS

- Italian National Scientific Qualification (Abilitazione Scientifica Nazionale) as Associate Professor, competition sector 06/M1 – Hygiene and Public Health, Nursing Sciences and Medical Statistics. Awarded 14 July 2025.
- State qualification for the profession of Biologist, University of Siena, 14 July 2015.

RESEARCH OUTPUT

- 71 peer-reviewed publications, 2 book chapters.
- Scopus metrics (August 2026): 68 documents, 1,224 citations, h-index 19.

GRANTS AND FUNDING AS PRINCIPAL INVESTIGATOR

MAP-N2 – Mapping age-dependent cross-reactive immunity to neuraminidase N2: implications for zoonotic influenza preparedness

Funder: University of Siena, Research Development Plan, New Frontiers 2025 call

Role: Principal investigator

Period: 1 January 2026 – 31 December 2027

A study of the human antibody response to the neuraminidase N2 of seasonal and avian influenza viruses, aimed at mapping anti-N2 immunity across birth cohorts and informing preparedness for zoonotic influenza viruses.

NATIONAL AND INTERNATIONAL RESEARCH PROJECTS

id.DRIVE – Surveillance of respiratory pathogens in adults hospitalised with SARI and field effectiveness of COVID-19 and RSV vaccines

Sponsor: P95

Role: Participation in the scientific activities of the project

Contribution to surveillance of respiratory pathogens in adults hospitalised with severe acute respiratory infection, and to the assessment of field effectiveness of COVID-19 and respiratory syncytial virus vaccines, with particular reference to the analysis and interpretation of virological, serological and epidemiological data.

Inno4Vac – Innovations to accelerate vaccine development and manufacture

Funder: IMI 2 JU, grant no. 101007799, supported by the European Union Horizon 2020 research and innovation programme and EFPIA

Role: Participation in the scientific activities of the project

Contribution to collaborative research aimed at developing and validating innovative approaches to accelerate vaccine development and manufacture, integrating immunology, big data, artificial intelligence, 3D tissue models and human infection models.

COVIDRIVE – Brand-specific field effectiveness of COVID-19 vaccines in preventing severe COVID-19 disease in Italy

Sponsor: P95 (partnership subsequently renamed id.DRIVE)

Role: Participation in the scientific activities of the project

Contribution to the assessment of brand-specific COVID-19 vaccine effectiveness in preventing laboratory-confirmed COVID-19 hospitalisation in patients with severe acute respiratory infection, including collection, analysis and interpretation of virological and epidemiological data.

COVI-VAC – Humoral immune response following administration of an mRNA COVID-19 vaccine in a prison healthcare facility

Funder: University of Siena, Research Support Plan 2021, Curiosity-driven call

Role: Participation in the scientific activities of the project

Contribution to the assessment of the humoral immune response following mRNA COVID-19 vaccination, with particular reference to neutralising antibodies against SARS-CoV-2.

Pfizer Global Medical Grants – A study of the antibody response to COVID-19 infection in Italy

Funder: Pfizer Global Medical Grants

Role: Participation in the scientific activities of the project

Contribution to a study of the antibody response following SARS-CoV-2 infection in asymptomatic and symptomatic individuals in Italy during the first phase of the COVID-19 pandemic, including serological analysis and interpretation of data in relation to the clinical and epidemiological picture.

TUSCAVIR.NET – Tuscany Antiviral Research Network

Funder: Regione Toscana, Bando Salute 2018

Role: Postdoctoral research fellow on the project

Validation and application of analytical processes for the assessment of in vitro cytotoxicity and antiviral activity of candidate compounds, including cell-based systems, antiviral activity assays and experimental analysis within a preclinical pipeline for the development of new antivirals.

ABNEURA – Development of serological assays for the quantification of anti-neuraminidase antibodies

Funder: Regione Toscana, POR FSE 2014–2020

Role: Postdoctoral research fellow on the project

Development and application of serological assays for the quantification of anti-neuraminidase antibodies, with particular reference to the antibody response to influenza viruses. Activities included optimisation of

immunological assays, analysis of biological samples and interpretation of serological data in the study of anti-neuraminidase immunity.

FLUCOP – Standardisation and development of assays for assessment of influenza vaccine correlates of protection

Funder: IMI JU, grant no. 115672, funded by the European Union Seventh Framework Programme FP7/2007–2013

Role: Postdoctoral research fellow on the project

Development, standardisation and application of immunological assays for the assessment of influenza vaccine correlates of protection, including contribution to multicentre collaborative studies on inter-laboratory comparability of serological assays and on improving tools for the assessment of influenza vaccine immunogenicity.

UNAVIR – Rare viral diseases: an innovative strategy to combat them with a single antiviral agent

Funder: Bando FAS Salute 2014

Role: Participation in the scientific activities of the project

Contribution to research on the development and preclinical assessment of antiviral strategies for the treatment of rare and emerging viral diseases, with particular reference to Chikungunya, Dengue and West Nile viruses.

CONSISE – Consortium for the Standardization of Influenza Seroepidemiology

Role: Participation in the scientific activities of the project

Contribution to collaborative activities aimed at the standardisation of influenza seroepidemiology and the development of investigation protocols for population studies and public health policy support.

TECHNICAL AND METHODOLOGICAL SKILLS

Serology and vaccine immunology

Development, standardisation and application of serological assays for the assessment of the antibody response to respiratory viruses, arboviruses and emerging pathogens. Expertise in virus neutralisation assays, including microneutralisation and plaque reduction neutralisation, enzyme-linked lectin assay (ELLA), ELISA and antibody avidity assays, indirect immunofluorescence, haemagglutination inhibition and single radial haemolysis.

Virology and cell culture

Isolation, growth and propagation of influenza and other respiratory viruses in cell culture and in embryonated eggs. Expertise in the production of pseudotyped viruses and in the maintenance and handling of human and animal cell lines.

Molecular biology and virological diagnostics

RT-PCR and real-time PCR. Certified training in the PROCLEIX WNV Assay on the PROCLEIX TIGRIS System (Novartis Diagnostics).

Sequencing

Certified training in the MiSeq next-generation sequencing platform (Illumina, Inc.). Experience in NGS sequencing using Nanopore technology (Oxford Nanopore Technologies Ltd).

Antiviral activity assessment and functional assays

Cytotoxicity and antiviral activity assays on human and animal cell lines. Expertise in immunofluorescence and in the acquisition and analysis of confocal microscopy images.

Biosafety and laboratory quality

Laboratory training for work in BSL-2 and BSL-3 environments. Certified training in Good Clinical Practice (GCP) and Good Clinical Laboratory Practice (GCLP) for analytical laboratory personnel, Qualogy Consultancy 2002 Ltd, 17 July 2018.

Software

Microsoft Office (Word, Excel, PowerPoint); data analysis and visualisation with GraphPad Prism; image analysis with ImageJ/Fiji; phylogenetic analysis with MEGA and Nextstrain; reference management with EndNote and Zotero.

SCIENTIFIC AND ACADEMIC AFFILIATIONS

Research centres

- Inter-university Centre for Research on Influenza and Other Transmissible Infections (CIRI-IT), affiliated since 25 May 2026.

Academies

- Accademia dei Fisiocritici, Siena — Ordinary Member since 1 January 2025.

Scientific societies

- Italian Society of Hygiene, Preventive Medicine and Public Health (SItI)
- European Public Health Association (EUPHA)
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
- International Society for Influenza and other Respiratory Virus Diseases (ISIRV)

SCIENTIFIC COMMITTEES

- VisMederi Foundation — Member of the Technical Scientific Committee, 9 September 2022 – 23 December 2025.

EDITORIAL ACTIVITY

- Virology Journal — Associate Editor since 1 June 2024.
- Vaccines (MDPI) — Guest Editor, Special Issue "SARS-CoV-2 Variants Research and Ending the COVID-19 Pandemic", completed 31 December 2022.
- Reviewer for international scientific journals in virology, immunology, vaccines, public health and infectious diseases.

TEACHING AND SUPERVISION

Doctoral faculty

- Member of the faculty board of the PhD programme "One Health Approaches to Infectious Diseases and Life Science Research" (XLII cycle), University of Pavia.

Course coordination — academic year 2025/2026

- Coordinator, Integrated Course in Human Sciences and Health Promotion, BSc in Nursing, University of Siena.
- Coordinator, Integrated Course in Microbiology and Hygiene, MSc in Dentistry and Dental Prosthodontics, University of Siena.

Teaching appointments — academic year 2025/2026

- Health Promotion module, 1 ECTS, 14 hours, Integrated Course in Human Sciences and Health Promotion, BSc in Nursing, first year, first semester, University of Siena.

- Hygiene module, 2 ECTS, 28 hours, Integrated Course in Human Sciences and Health Promotion, BSc in Nursing, first year, first semester, University of Siena.
- General and Applied Hygiene I module, 4 ECTS, 48 hours, Integrated Course in Microbiology and Hygiene, MSc in Dentistry and Dental Prosthodontics, third year, University of Siena.

Teaching appointments — academic year 2024/2025

- Hygiene module, 2 ECTS, 28 hours, Integrated Course in Human Sciences and Health Promotion, BSc in Nursing, first year, first semester, University of Siena.
- General and Applied Hygiene I module, 4 ECTS, 48 hours, Integrated Course in Microbiology and Hygiene, MSc in Dentistry and Dental Prosthodontics, third year, University of Siena.

Teaching collaboration — academic year 2023/2024

- Hygiene module, Integrated Course in Human Sciences and Health Promotion, BSc in Nursing, University of Siena.
- General and Applied Hygiene II module, Integrated Course in Microbiology and Hygiene, MSc in Dentistry and Dental Prosthodontics, University of Siena.

Seminars and advanced training

- "Recent updates on correlates of vaccine-induced protection", PhD Week 2024 "Navigating the Future in Healthcare Science", Pisa, 15–17 May 2024.

Thesis supervision

- Supervisor and co-supervisor of undergraduate and master's theses in Biotechnology, Medical Biotechnologies, Health Biology and Molecular Biology, University of Siena.
- Co-supervisor of master's theses in Medical and Pharmaceutical Biotechnology, University of Florence.

ORAL PRESENTATIONS AT SCIENTIFIC CONFERENCES

Invited oral presentations

- Beyond National Averages: Reaching Zero-Dose Children and Strengthening Vaccine Confidence — Lessons from Italy. 25th International Vaccinology Course (IVI), 31 Agosto – 4 Settembre 2026.
- Evaluation of Mpox- and Vaccinia-virus neutralizing antibodies before and after smallpox vaccination: a seroepidemiological study. 10th IBP Biosafety Conference, Siena, 11–12 September 2024.

Contributed oral presentations

- Prevalence of influenza B/Yamagata viruses from season 2012/2013 to 2021/2022 in Italy as an indication of a potential lineage extinction. Options for the Control of Influenza XII, Brisbane, 29 September – 2 October 2024.
- Prevalence of influenza B/Yamagata viruses from season 2012/2013 to 2021/2022 in Italy as an indication of a potential lineage extinction. Influenza Vaccines for the World, Siena, 21–23 May 2024.
- Potential extinction of influenza B/Yamagata: antibody trends from 2012/2013 to 2021/2022 in Italy. 56th SItI National Congress, Rome, 2–6 May 2023.
- SARS-CoV-2 circulation during the first year of the pandemic: results of a seroepidemiological study in Tuscany, January to December 2020. XXX SItI Sicilian-Calabrian Interregional Congress, Lipari, 26–28 May 2022.
- Serum neutralizing activity against SARS-CoV-2 variants in hospitalized COVID-19 patients. 14th European Public Health Conference, virtual edition, 10–12 November 2021.
- Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection. 14th European Public Health Conference, virtual edition, 10–12 November 2021.
- Twenty years of measles immunity in Italy: how far is the elimination target? 54th SItI National Congress, Lecce, 3–6 November 2021.

LANGUAGES

- Italian — native speaker.
- English — B2. First Certificate in English (ESOL), June 2006.
- German — A2. Bilingual diploma.

PEER-REVIEWED PUBLICATIONS

** corresponding author; † equal contribution / co-first author*

1. Trombetta CM, Marotta MG, **Marchi S**, Bonfante F, Maniero S, Napolitano A, Moreno A, Chiapponi C, Temperton N, Scott S, Daly JM, Manenti A, Montomoli E, Lanave G, Camero M, Martella V. Exposure of dogs to influenza A and B viruses. *One Health*. 2026. doi: 10.1016/j.onehlt.2026.101537.
2. Di Placido D, Ciaramella A, Riccomi A, Trombetta CM, Dorrucci M, Farchi F, Giuseppetti R, **Marchi S**, Sanarico N, Pezzotti P, et al. Association Between Immunosuppressive Cell Populations and Immune Response to Influenza Vaccination in Younger and Older Adults. *Vaccines*. 2026; 14(8):680. doi: 10.3390/vaccines14080680
3. Sieghart D, Jordakieva G, Dürschmid C, Hana CA, Tran LV, Heinz LX, Haslacher H, Zlesak M, Marzoner V, Nasztl P, Piccini G, Manenti A, Montomoli E, Jorda A, Fedrizzi C, Hasenoehrl T, Zdravkovic A, Anderle K, Wiedermann U, Drapalik S, Steinbrecher H, Bergmann F, Firbas C, Wagner B, Leonardi M, Pierleoni G, Ballini M, Benincasa L, **Marchi S**, Trombetta CM, Perkmann T, Crevenna R, Zeitlinger M, Bonelli M, Aletaha D, Radner H. Impact of ABO Blood System on Immunogenicity and Vaccine Efficacy of COVID-19 Booster Vaccination-A Population-Based Study of 3066 Individuals. *Influenza Other Respir Viruses*. 2026 Aug;20(8):e70300. doi: 10.1111/irv.70300.
4. Falsini A, Coppola C, Fiori A, Buonavoglia D, **Marchi S**, Montomoli E, Pellegrini F, Lanave G, Martella V, Camero M, Trombetta CM. Influenza D Virus Circulation Among Bovines, Swine, Equines, and Wild Boars in Italy: A Sero-Epidemiological Study. *Pathogens*. 2025 14(9), 891. doi: 10.3390/pathogens14090891.
5. **Marchi S***, Salvestroni V, Bocci BM, Guarducci G, Milano G, De Francesco AC, Montomoli E, Bova G, Camarri A, Manini I. SARS-CoV-2, influenza, HRSV and other respiratory pathogens during the post-COVID-19 era: epidemic circulation in Italy in the 2023/2024 season. *J Infect Public Health*. 2025 18:11. doi: 10.1016/j.jiph.2025.102905.
6. Molina Estupiñan JL, Foroutan Pajooian P, Pedersen G, Christensen D, **Marchi S**, Montomoli E, Bjarnarson SP, Jonsdottir I, Aradottir Pind AA. Dose sparing effects of novel adjuvants and aluminium hydroxide on two different vaccines in a neonatal mouse model. *Front Immunol*. 2025 July 16:1646677. doi: 10.3389/fimmu.2025.1646677.
7. **Marchi S***, Piccini G, Remarque EJ, Roscia G, Semplici B, Cantaloni P, Guerrini N, Zannella R, Coluccio R, Benincasa L, Solfanelli N, Trombetta CM, Montomoli E, Manenti A. Correlation between Microneutralization Test and a Multiplexed Immunoassay for evaluation of Monkeypox and Vaccinia virus antibodies before and after smallpox vaccination. *Front Immunol*. 2025 June 23. doi: 10.3389/fimmu.2025.1585284.
8. Amodeo D, **Marchi S**, Fiaschi L, Raucci L, Biba C, Salvestroni V, Trombetta CM, Manini I, Zazzi M, Montomoli E, Vicenti I, Cevenini G, Messina G. Analysis of the SARS-CoV-2 inactivation mechanism using violet-blue light (405 nm). *Appl Environ Microbiol*. 2025 May 14:e0040325. doi: 10.1128/aem.00403-25.
9. **Marchi S**, Amodeo D, Peccetti B, De Palma I, Messina G, Montomoli E, Trombetta CM. The virucidal potential effects of violet-blue light on influenza D virus. *Photochem Photobiol Sci*. 2025 Mar 26. doi: 10.1007/s43630-025-00708-9.
10. Grassi T, Bagordo F, Rota MC, Dettori M, Baldovin T, Napolitano F, Panico A, Massaro E, **Marchi S**, Furfaro G, Immordino P, Savio M, Gabutti G; Sero-epidemiological Study Group. Seroprevalence of measles antibodies in the Italian general population in 2019-2020. *Vaccine*. 2024 Sep 17;42(22):126012. doi: 10.1016/j.vaccine.2024.05.060.
11. **Marchi S**, Guarducci G, Marotta MG, Peccetti B, Viviani S, Messina G, Montomoli E, Martella V, Camero M, Trombetta CM. Improving the ONE HEALTH approach: a lesson from SARS-CoV-2 pandemic. *J Prev Med Hyg*. 2024 Oct 18, 65: E312-322. doi: 10.15167/2421-4248/jpmh2024.65.3.3187
12. **Marchi S***, Bruttini M, Milano G, Manini I, Chironna M, Pariani E, Manenti A, Kistner O, Montomoli E, Temperton N, Trombetta CM. Prevalence of Influenza B/Yamagata Viruses From Season 2012/2013 to 2021/2022 in Italy as an Indication of a Potential Lineage Extinction. *Influenza Other Respir Viruses*. 2024 Sep, 18(9): e13359. doi: 10.1111/irv.13359
13. Trombetta CM, Accardi G, Aiello A, Calabrò A, Caruso C, Ligotti ME, **Marchi S**, Montomoli E, Neto MM, Temperton N, Candore G. Centenarians, semi and supercentenarians, COVID-19 and Spanish flu: a serological assessment to gain insight into the resilience of older centenarians to COVID-19. *Immun Ageing*. 2024 Jun 27;21(1):44. doi: 10.1186/s12979-024-00450-3.
14. **Marchi S***, Piccini G, Cantaloni P, Guerrini N, Zannella R, Coluccio R, Benincasa L, Solfanelli N, Remarque EJ, Viviani S, Kistner O, Temperton N, Montomoli E, Manenti A, Trombetta CM. Evaluation of monkeypox- and vaccinia-virus

- neutralizing antibodies before and after smallpox vaccination: A sero-epidemiological study. *J Med Virol.* 2024 Jun;96(6):e29728. doi: 10.1002/jmv.29728.
15. Bagordo F, Grassi T, Rota MC, Castiglia P, Baldovin T, Della Polla G, Panico A, Ogliastro M, **Marchi S**, Vicentini C, Immordino P, Savio M, Gabutti G; Sero-epidemiological Study Group. Seroprotection against tetanus in the Italian general population. *Vaccine.* 2024 May 17:S0264-410X(24)00561-9. doi: 10.1016/j.vaccine.2024.05.015
 16. Riccomi A, Trombetta CM, Dorrucchi M, Di Placido D, Sanarico N, Farchi F, Giuseppetti R, Villano U, Marcantonio C, **Marchi S**, Ciaramella A, Pezzotti P, Montomoli E, Valdarchi C, Ciccaglione AR, Vendetti S. Effects of influenza vaccine on the immune responses to SARS-CoV-2 vaccination. *Vaccines* 2024, 12, 425. doi: 10.3390/vaccines12040425
 17. Milano G, **Marchi S**, Vicenti I, Biba C, Fiaschi L, Trombetta CM, Lazzeri G, Montomoli E, Manini I. SARS-CoV-2 and influenza virus coinfections in the Tuscan population during the 2021/2022 influenza season. *J Prev Med Hyg.* 2024 Apr 15; 65: E11-E16. doi: 10.15167/2421-4248/jpmh2024.65.1.3179.
 18. Sieghart D, Hana CA, Dürschmid C, Heinz LX, Haslacher H, Zlesak M, Piccini G, Manenti A, Montomoli E, Jorda A, Fedrizzi C, Hasenoehrl T, Zdravkovic A, Anderle K, Wiedermann U, Drapalik S, Steinbrecher H, Bergmann F, Firbas C, Jordakieva G, Wagner B, Leonardi M, Pierleoni G, Ballini M, Benincasa L, **Marchi S**, Trombetta C, Perkmann T, Crevenna R, Zeitlinger M, Bonelli M, Aletaha D, Radner H. Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy. *J Clin Virol.* 2024 Feb 28;173:105661. doi: 10.1016/j.jcv.2024.105661.
 19. Trombetta CM, **Marchi S**, Marotta MG, Chiapponi C, Montomoli E, Lanave G, Camero M, Martella V. Detection of influenza D antibodies in dogs, Apulia region, Italy, 2016–2023. *Emerg Infect Dis.* 2024 May; 30: 1045-1047. doi: 10.3201/eid3005.231401.
 20. Lanave G, Camero M, Coppola C, **Marchi S**, Cascone G, Salina F, Coltraro M, Odigie AE, Montomoli E, Chiapponi C, Cicirelli V, Martella V, Trombetta CM. Serological evidence for circulation of influenza D virus in the ovine population in Italy. *Pathogens.* 2024 Feb 11;13(2):162. doi: 10.3390/pathogens13020162.
 21. Angeletti PM, **Marchi S**, Trombetta CM, Altobelli E. Flu vaccine administration in the period before SARS-CoV-2 infection and its outcomes: an umbrella review. *Preventive Medicine Reports.* 2023. doi: 10.1016/j.pmedr.2023.102575
 22. Trombetta CM, **Marchi S**†, Leonardi M, Coppola C, Benincasa L, Marotta MG, Buonvino N, Maes P, Stufano A, Pontrelli D, Vasinioti VI, Manenti A, Camero M, Montomoli E, Decaro N, Lovreglio P. Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy. *Acta Tropica.* 2023. doi: 10.1016/j.actatropica.2023.107042
 23. **Marchi S**, Fallani E, Salvatore M, Montomoli E, Trombetta CM. The burden of influenza and the role of influenza vaccination in adults aged 50-64 years: A summary of available evidence. *Hum Vaccin Immunother.* 2023 Aug;19(2):2257048. doi: 10.1080/21645515.2023.2257048
 24. Bonifazi C, Trombetta CM, Barneschi I, Latanza S, Leopoldi S, Benincasa L, Leonardi M, Semplici C, Piu P, **Marchi S***, Montomoli E, Manenti A. Establishment and validation of a High-throughput Micro-Neutralization assay for Respiratory Syncytial Virus (subtypes A and B). *J Med Virol.* 2023 Jul;95(7):e28923. doi: 10.1002/jmv.28923
 25. Manenti A, Solfanelli N, Cantaloni P, Mazzini L, Leonardi M, Benincasa L, Piccini G, **Marchi S**, Boncioli M, Spertilli Raffaelli C, Tacconi D, Mattiuzzo G, Kistner O, Montomoli E, Trombetta CM. Evaluation of Monkeypox-and Vaccinia virus-neutralizing antibodies in human serum samples after vaccination and natural infection. *Front Public Health.* 2023 Jun 21; 11. doi: 10.3389/fpubh.2023.1195674
 26. Waldoock J, Remarque EJ, Zheng L, Ho S, Hoschler K, Neumann Britta, Sediri-Schön H, Trombetta CM, Montomoli E, **Marchi S**, Lapini G, Zhou F, Lartey SL, Cox RJ, Facchini M, Castrucci MR, Friel D, Olliger T, Caillet C, Music N, Palladino G, Engelhardt OG. Haemagglutination inhibition and virus microneutralisation serology assays: use of harmonised protocols and biological standards in seasonal influenza serology testing and their impact on inter-laboratory variation and assay correlation: A FLUCOP collaborative study. *Front Immunol.* 2023 Apr 18;14:1155552. doi: 10.3389/fimmu.2023.1155552
 27. Waldoock J, Weiss C, Wang W, Levine MZ, Jefferson SN, Ho S, Hoschler K, Londt BZ, Masat E, Carolan L, Sanchez-Ovando S, Fox A, Watanabe S, Akimoto M, Sato A, Kishida N, Buys A, Maake L, Fourie C, Caillet C, Raynaud S, Webby R, Debeauchamp J, Cox R, Lartey SL, Trombetta CM, **Marchi S**, Montomoli E, Munoz IS, Eiros JM, Sanchez-Martinez J, Duijsings D, Engelhardt OG. An External Quality Assessment feasibility study; cross laboratory comparison of haemagglutination inhibition assay and microneutralisation assay performance for seasonal influenza serology testing: a FLUCOP study. *Front Immunol.* 2023 Feb 28;14:1129765. doi: 10.3389/fimmu.2023.1129765
 28. **Marchi S***, Coppola C, Piu P, Benincasa L, Dapporto F, Manenti A, Viviani S, Montomoli E, Trombetta CM. SARS-CoV-2 epidemiological trend before vaccination era: a seroprevalence study in Apulia, Southern Italy, in 2020. *J Public Health (Berl).* 2023 Feb 4:1-6. doi: 10.1007/s10389-023-01834-3
 29. Trombetta CM, **Marchi S**, Leonardi M, Stufano A, Lorusso E, Montomoli E, Decaro N, Buonvino N, Lovreglio P. Evaluation of antibody response to SARS-CoV-2 variants after 2 doses of mRNA COVID-19 vaccine in a correctional facility. *Hum Vaccin Immunother.* 2022 Dec 30;18(7):2153537. doi: 10.1080/21645515.2022.2153537.

30. **Marchi S***, Dragoni F, Boccuto A, Idoko OT, Zazzi M, Sow S, Diallo A, Viviani S, Montomoli E, Vicenti I, Trombetta CM. Neutralizing activity of African lineage Zika virus immune sera towards Asian lineage. *Acta Trop.* 2022, 237:106736. doi: 10.1016/j.actatropica.2022.106736
31. Dapporto F, Leonardi M, Trombetta CM, Semplici C, Piu P, Piccini G, Benincasa L, **Marchi S**, Andreano E, Lovreglio P, Buonvino N, Decaro N, Stufano A, Lorusso E, Bombardieri E, Ruello A, Viviani S, Rappuoli R, Molesti E, Manenti A and Montomoli E. The neutralizing response to SARS-CoV-2 Omicron Variants BA.1 and BA.2 in COVID-19 patients and homologous and heterologous vaccinees. *Hum Vaccin Immunother.* 2022 Nov 30;18(6):2129196. doi: 10.1080/21645515.2022.2129196
32. Trombetta CM, Piccini G, Pierleoni G, Leonardi M, Dapporto F, **Marchi S**, Andreano E, Paciello I, Benincasa L, Lovreglio P, Buonvino N, Decaro N, Stufano A, Lorusso E, Bombardieri E, Ruello A, Viviani S, Rappuoli R, Molesti E, Manenti A and Montomoli E. Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations. *Commun Biol* 2022 Sep 2;5(1):903. doi: 10.1038/s42003-022-03849-0
33. Dapporto F, **Marchi S**†, Leonardi M, Piu P, Lovreglio P, Decaro N, Buonvino N, Stufano A, Lorusso E, Bombardieri E, Ruello A, Viviani S, Molesti E, Trombetta CM, Manenti A and Montomoli E. Antibody avidity and neutralizing response against SARS-CoV-2 Omicron variant after infection or vaccination. *J Immunol Res.* 2022 Aug 31;2022:4813199. doi: 10.1155/2022/4813199
34. Stufano A, Buonvino N, Trombetta CM, Pontrelli D, **Marchi S**, Lobefaro G, De Benedictis L, Lorusso E, Carofiglio MT, Vasinioti VI, Montomoli E, Decaro N, Lovreglio P. COVID-19 Outbreak and BNT162b2 mRNA Vaccination Coverage in a Correctional Facility during Circulation of the SARS-CoV-2 Omicron BA.1 Variant in Italy. *Vaccines* 2022 Jul 17;10(7):1137. doi: 10.3390/vaccines10071137
35. **Marchi S***, Lanave G, Camero M, Dapporto F, Manenti A, Benincasa L, Acciavatti A, Brogi G, Viviani S, Montomoli E, Trombetta CM. SARS-CoV-2 circulation during the first year of the pandemic: a seroprevalence study from January to December 2020 in Tuscany, Italy. *Viruses* 2022, 2022 Jun 30;14(7):1441. doi: 10.3390/v14071441
36. Bernard MC, Waldock J, Commandeur S, Strauss L, Trombetta CM, **Marchi S**, Zhou F, van de Witte S, van Amsterdam P, Ho S, Hoschler K, Lugovtsev V, Weir JP, Montomoli E, Cox RJ, Engelhardt OG, Friel D, Wagner R, Olliger T, Germain S, Sediri-Schon H. Validation of a Harmonized Enzyme-Linked-Lectin-Assay (ELLA-NI) Based Neuraminidase Inhibition Assay Standard Operating Procedure (SOP) for Quantification of N1 Influenza Antibodies and the Use of a Calibrator to Improve the Reproducibility of the ELLA-NI With Reverse Genetics Viral and Recombinant Neuraminidase Antigens: A FLUCOP Collaborative Study. *Front Immunol.* 2022 Jun 17;13:909297. doi: 10.3389/fimmu.2022.909297
37. Trombetta CM, **Marchi S**, Montomoli E. The baculovirus expression vector system: a modern technology for the future of influenza vaccine manufacturing. *Expert Rev Vaccines.* 2022 Sep;21(9):1233-1242. doi: 10.1080/14760584.2022.2085565
38. Trombetta CM, Kistner O, Montomoli E, Viviani S, **Marchi S**. Influenza viruses and vaccines: the role of vaccine effectiveness studies for evaluation of the benefits of influenza vaccines. *Vaccines* 2022 May 1;10(5):714. doi: 10.3390/vaccines10050714
39. Buonavoglia A, Lanave G, **Marchi S***, Lorusso P, Montomoli E, Martella V, Camero M, Prati C, Trombetta CM. In vitro virucidal activity of mouthwashes on SARS-CoV-2. *Oral Dis*, 2022 Nov;28 Suppl 2:2509-2515. doi: 10.1111/odi.14205
40. Trombetta CM, **Marchi S**, Viviani S, Manenti A, Casa E, Dapporto F, Remarque EJ, Bollati V, Manini I, Lazzeri G, Montomoli E. A serological investigation in Southern Italy: was SARS-CoV-2 circulating in late 2019? *Hum Vaccin Immunother.* 2022 Nov 30;18(5):2047582. doi: 10.1080/21645515.2022.2047582
41. Trombetta CM, Montomoli E, Di Bartolo I, Ostanello F, Chiapponi C, **Marchi S**. Detection of antibodies against Influenza D virus in swine veterinarians in Italy in 2004. *J Med Virol.* 2022 Jun;94(6):2855-2859. doi: 10.1002/jmv.27466
42. Vicenti I, Martina MG, Boccuto A, De Angelis M, Giavarini G, Dragoni F, **Marchi S**, Trombetta CM, Crespan E, Maga G, Eydoux C, Decroly E, Montomoli E, Nencioni L, Zazzi M, Radi M. System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2. *Eur J Med Chem.* 2021 Nov 15;224:113683.. doi: 10.1016/j.ejmech.2021.113683
43. **Marchi S***, Remarque EJ, Viviani S, Rizzo C, Monteverde Spencer GT, Coluccio R, Montomoli E, Trombetta CM. Measles immunity over two decades in two large Italian regions: how far is the elimination goal? *Vaccine.* 2021 Sep 24;39(40):5928-5933. doi: 10.1016/j.vaccine.2021.08.001
44. Trombetta CM, Viviani S, Montomoli E, **Marchi S**. Seroprevalence of antibodies to cytomegalovirus in pregnant women in the Apulia region (Italy). *J Prev Med Hyg.* 2021 Jul 30;62(2):E372-E376. doi: 10.15167/2421-4248/jpmh2021.62.2.1800
45. **Marchi S**, Viviani S, Remarque EJ, Ruello A, Bombardieri E, Bollati V, Milani GP, Manenti A, Lapini G, Rebuffat A, Montomoli E, Trombetta CM. Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection. *PLoS One.* 2021 Jul 2;16(7):e0253977. doi: 10.1371/journal.pone.0253977

46. **Marchi S***, Montomoli E, Viviani S, Giannecchini S, Stincarelli MA, Lanave G, Camero M, Alessio C, Coluccio R, Trombetta CM. West Nile virus seroprevalence in the Italian Tuscany region from 2016 to 2019. *Pathogens*. 2021 Jul 5;10(7):844. doi: 10.3390/pathogens10070844
47. Trombetta CM, **Marchi S**, Viviani S, Manenti A, Benincasa L, Ruello A, Bombardieri E, Vicenti I, Zazzi M, Montomoli E. Serum Neutralizing activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 variants of concern in hospitalized COVID-19 patients. *Viruses*. 2021 Jul 12;13(7):1347. doi: 10.3390/v13071347
48. Manini I, Camarri A, **Marchi S**, Trombetta CM, Vicenti I, Dragoni F, Lazzeri G, Bova G, Montomoli E and Capecci PL. Surveillance for Severe Acute Respiratory Infections among Hospitalized Subjects from 2015/2016 to 2019/2020 Seasons in Tuscany, Italy. *Int J Environ Res Public Health*. 2021 Apr 7;18(8):3875. doi: 10.3390/ijerph18083875
49. Milani GP, Rota F, Favero C, Dioni L, Manenti A, Hoxha M, Pariani E, Albetti B, Pesatori AC, Montomoli E, Bollati V, on behalf of the UNICORN Consortium investigators. Detection of IgM, IgG and SARS-CoV-2 RNA among the personnel of the University of Milan, March through May 2020: the UNICORN study. *BMJ Open* 2021;11:e046800. doi:10.1136/bmjopen-2020-046800
50. Pavulraj S, Bergmann T, Trombetta CM, **Marchi S**, Montomoli E, El Alami SS, Ragni-Alunni R, Osterrieder N and Azab W. Immunogenicity of Calvenza-03 EIV/EHV® Vaccine in Horses: Comparative In Vivo Study. *Vaccines (Basel)*. 2021 Feb 17;9(2):166. doi: 10.3390/vaccines9020166
51. Mazzini L, Martinuzzi D, Hyseni I, Benincasa L, Molesti E, Casa E, Lapini G, Piu P, Trombetta CM, **Marchi S**, Razzano I, Manenti A, Montomoli E. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples. *J Immunol Methods*. 2021 Feb;489:112937. doi: 10.1016/j.jim.2020.112937.
52. **Marchi S**, Monti M, Viviani S, Remarque EJ, Esposito S, Principi N, Ruggiero L, Montomoli E, Trombetta CM. Immunity for measles in Italian children and adolescents: a persistent problem in view of measles elimination. *J Public Health (Oxf)*. 2021 Dec 10;43(4):e601-e609. doi: 10.1093/pubmed/fdaa153
53. Milani GP, Dioni L, Favero C, Cantone L, Macchi C, Delbue S, Bonzini M, Montomoli E, Bollati V, Albetti B, Bandi C, Bellini T, Buscaglia M, Cantarella C, Carugno M, Casartelli S, D'Alessandro S, De Chiara F, Eberini I, Ferrari L, Ferraroni M, Galastri L, Galli C, Hoxha M, Iodice S, La Vecchia C, Manenti A, Manini I, **Marchi S**, Mariani J, Pariani E, Pesatori AC, Rota F, Ruscica M, Schioppo T, Tarantini L, Trombetta CM, Vicenzi M, Zanchetta G. Serological follow-up of SARS-CoV-2 asymptomatic subjects. *Sci Rep*. 2020 Nov 18;10(1):20048. doi: 10.1038/s41598-020-77125-8.
54. **Marchi S**, Manini I, Kistner O, Piu P, Remarque EJ, Manenti A, Biuso F, Carli T, Lazzeri G, Montomoli E and Trombetta CM. Serologically-Based Evaluation of Cross-Protection Antibody Responses among Different A(H1N1) Influenza Strains. *Vaccines (Basel)*. 2020 Nov 5;8(4):656. doi: 10.3390/vaccines8040656
55. Milani GP, Montomoli E, Bollati V, Albetti B, Bandi C, Bellini T, Bonzini M, Buscaglia M, Cantarella C, Cantone L, Carugno M, Casartelli S, Cavaletti G, D'Alessandro S, De Chiara F, Delbue S, Dioni L, Eberini I, Favero C, Ferrari L, Ferraroni M, Galastri L, Galli C, Hoxha M, Iodice S, La Vecchia C, Macchi C, Manini I, **Marchi S**, Mariani J, Pariani E, Pesatori AC, Rota F, Ruscica M, Schioppo T, Tarantini L, Trombetta CM, Valsecchi MG, Vicenzi M, Zanchetta G. SARS-CoV-2 infection among asymptomatic homebound subjects in Milan, Italy. *Eur J Intern Med*. 2020 Aug;78:161-163. doi: 10.1016/j.ejim.2020.06.010
56. **Marchi S**, Viviani S, Montomoli E, Tang Y, Boccuto A, Vicenti I, Zazzi M, Sow S, Diallo A, Idoko OT, Bhat N, Trombetta CM. Zika Virus in West Africa: A Seroepidemiological Study between 2007 and 2012. *Viruses*. 2020 Jun 13;12(6):641. doi: 10.3390/v12060641
57. Trombetta CM, Montomoli E, Viviani S, Coluccio R, **Marchi S**. Evaluation of Varicella Immunity during Pregnancy in Apulia Region, Southern Italy. *Vaccines (Basel)*. 2020 May 10;8(2):214. doi: 10.3390/vaccines8020214
58. Manenti A, Maggetti M, Casa E, Martinuzzi D, Torelli A, Trombetta CM, **Marchi S**, Montomoli E. Evaluation of SARS-CoV-2 neutralizing antibodies using of a CPE-based Colorimetric live virus micro-neutralization assay in human serum samples. *J Med Virol*. 2020 Oct;92(10):2096-2104. doi: 10.1002/jmv.25986
59. **Marchi S**, Viviani S, Montomoli E, Trombetta CM. Measles susceptibility in Apulia: the Italian mirror? *J Infect Dis*. 2020 Sep 14;222(8):1414-1415. doi: 10.1093/infdis/jiaa212
60. Brai A, Boccuto A, Monti M, **Marchi S**, Vicenti I, Saladini F, Trivisani CI, Pollutri A, Trombetta CM, Montomoli E, Riva V, Garbelli A, Nola EM, Zazzi M, Maga G, Dreassi E, Botta M. Exploring the Implication of DDX3X in DENV Infection: Discovery of the First-in-Class DDX3X Fluorescent Inhibitor. *ACS Med Chem Lett*. 2020 Apr 9;11(5):956-962. doi: 10.1021/acsmchemlett.9b00681
61. Fanigliulo D, **Marchi S**, Montomoli E, Trombetta CM. Toxoplasma gondii in women of childbearing age and during pregnancy: seroprevalence study in Central and Southern Italy from 2013 to 2017. *Parasite*. 2020;27:2. doi: 10.1051/parasite/2019080
62. **Marchi S**, Viviani S, Montomoli E, Trombetta CM. Elimination of congenital rubella: a seroprevalence study of pregnant women and women of childbearing age in Italy. *Hum Vaccin Immunother*. 2020 Apr 2;16(4):895-898. doi: 10.1080/21645515.2019.1688041

63. Trombetta CM, **Marchi S**, Manini I, Kistner O, Li F, Piu P, Manenti A, Biuso F, Sreenivasan C, Druce J, Montomoli E. Influenza D virus: serological evidence in the Italian population from 2005 to 2017. *Viruses*. 2019 Dec 27;12(1):30. doi: 10.3390/v12010030
64. **Marchi S**, Montomoli E, Remarque EJ, Monteverde Spencer GT, Azzarello A, Viviani S, Trombetta CM. Pertussis over two decades: a seroepidemiological study in a large population of the Siena Province, Tuscany Region, Central Italy. *BMJ Open*. 2019 Oct 30;9(10):e032987. doi: 10.1136/bmjopen-2019-032987
65. Trombetta CM, **Marchi S**, Manini I, Lazzeri G, Montomoli E. Challenges in the development of egg-independent vaccines for influenza. *Expert Rev Vaccines*. 2019 Jul;18(7):737-750. doi: 10.1080/14760584.2019.1639503
66. **Marchi S**, Monti M, Viviani S, Montomoli E, Trombetta CM. Measles in pregnancy: a threat for Italian women? *Hum Vaccin Immunother*. 2019;15(12):2851-2853. doi: 10.1080/21645515.2019.1621146
67. **Marchi S**, Viviani S, Montomoli E, Trombetta CM. Low prevalence of antibodies against pertussis in pregnant women in Italy. *Lancet Infect Dis*. 2019 Jul;19(7):690. doi: 10.1016/S1473-3099(19)30269-5
68. Trombetta CM, Olivieri C, Cox RJ, Remarque EJ, Centi C, Perini D, Piccini G, Rossi S, **Marchi S**, Montomoli E. Impact of erythrocyte species on assays for influenza serology. *J Prev Med Hyg*. 2018 Mar 30;59(1):E1-E7. doi: 10.15167/2421-4248/jpmh2018.59.1.870
69. **Marchi S**, Trombetta CM, Gasparini R, Temperton N, Montomoli E. Epidemiology of herpes simplex virus type 1 and 2 in Italy: a seroprevalence study over 15 years. *J Prev Med Hyg*. 2017 Mar;58(1):E27-E33. doi: 10.15167/2421-4248/jpmh2017.58.1.686
70. **Marchi S**, Trombetta CM, Kistner O, Montomoli E. Seroprevalence study of Toscana virus and viruses belonging to the Sandfly fever Naples antigenic complex in central and southern Italy. *J Infect Public Health*. 2017 Nov-Dec;10(6):866-869. doi: 10.1016/j.jiph.2017.02.001
71. Bacci A, **Marchi S**, Fievet N, Massougboji A, Perrin RX, Chippaux JP, Sambri V, Landini MP, Varani S, Rossini G. High Seroprevalence of Chikungunya virus antibodies among pregnant women living in an urban area in Benin, West Africa. *Am J Trop Med Hyg*. 2015 Jun;92(6):1133-6. doi: 10.4269/ajtmh.14-0092.

BOOK CHAPTERS

1. Montomoli E, **Marchi S**, Giancchetti E. Chapter XIV – Vaccinations. In: *La responsabilità del medico di famiglia. Aspetti medico-legali e giuridici della professione*. Maggioli Editore, June 2023.
2. **Marchi S**, Trombetta CM, Montomoli E. Emerging and Re-emerging Arboviral Diseases as a Global Health Problem. In: *Public Health – Emerging and Re-emerging Issues*. IntechOpen, October 2018. doi: 10.5772/intechopen.77382.

CONFERENCE PROCEEDINGS

1. Dragoni L, Amodeo D, Cevenini G, **Marchi S**, Trombetta C, Nante N, Messina G. Viricidal activity of antimicrobial blue light (405 nm) against the SARS-CoV-2 and influenza virus. *Eur J Public Health*. 2023 Oct 24;33(Suppl 2):ckad160.1044. doi: 10.1093/eurpub/ckad160.1044.
2. **Marchi S**. Serum neutralizing activity against SARS-CoV-2 variants in hospitalized COVID-19 patients. *Eur J Public Health*. 2021 Oct 20;31(Suppl 3):ckab164.097. doi: 10.1093/eurpub/ckab164.097.
3. **Marchi S**. Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection. *Eur J Public Health*. 2021 Oct 20;31(Suppl 3):ckab164.814. doi: 10.1093/eurpub/ckab164.814.
4. **Marchi S**, Viviani S, Montomoli E, Tang Y, Boccuto A, Vicenti I, Zazzi M, Sow S, Diallo A, Idoko OT, Bhat N, Trombetta CM. Zika Virus Epidemiology in Selected West African Countries between 2007 and 2012. *Proceedings*. 2020;50(1):100. doi: 10.3390/proceedings2020050100.
5. Trombetta CM, **Marchi S**, Manini I, Kistner O, Li F, Piu P, Manenti A, Biuso F, Sreenivasan C, Druce J, Montomoli E. Influenza D Virus: A Potential Threat for Humans? *Proceedings*. 2020;50(1):36. doi: 10.3390/proceedings2020050036.